Shin Nippon Biomedical Laboratories Balance Sheet Health
Financial Health criteria checks 3/6
Shin Nippon Biomedical Laboratories has a total shareholder equity of ¥36.5B and total debt of ¥35.0B, which brings its debt-to-equity ratio to 95.9%. Its total assets and total liabilities are ¥89.0B and ¥52.5B respectively. Shin Nippon Biomedical Laboratories's EBIT is ¥1.9B making its interest coverage ratio 59.1. It has cash and short-term investments of ¥11.2B.
Key information
95.9%
Debt to equity ratio
JP¥34.96b
Debt
| Interest coverage ratio | 59.1x |
| Cash | JP¥11.21b |
| Equity | JP¥36.45b |
| Total liabilities | JP¥52.53b |
| Total assets | JP¥88.98b |
Recent financial health updates
No updates
Recent updates
Shin Nippon Biomedical Laboratories (TSE:2395) Will Pay A Dividend Of ¥30.00
Dec 19
Shin Nippon Biomedical Laboratories (TSE:2395) Is Paying Out A Dividend Of ¥30.00
Dec 02What Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) 25% Share Price Gain Is Not Telling You
Nov 25Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Sep 19Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts
Aug 09Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding
Aug 06Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Jul 26Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Jul 12Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems
May 21Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 10Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00
Mar 12Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00
Feb 27Financial Position Analysis
Short Term Liabilities: 2395's short term assets (¥34.0B) exceed its short term liabilities (¥28.8B).
Long Term Liabilities: 2395's short term assets (¥34.0B) exceed its long term liabilities (¥23.7B).
Debt to Equity History and Analysis
Debt Level: 2395's net debt to equity ratio (65.2%) is considered high.
Reducing Debt: 2395's debt to equity ratio has increased from 67% to 95.9% over the past 5 years.
Debt Coverage: 2395's debt is not well covered by operating cash flow (4.7%).
Interest Coverage: 2395's interest payments on its debt are well covered by EBIT (59.1x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 19:38 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shin Nippon Biomedical Laboratories, Ltd. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuki Tsukamoto | BofA Global Research |
| Akitada Iwasa | Daiwa Securities Co. Ltd. |
| Masao Yoshida | Ichiyoshi Research Institute Inc. |